Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials.
J Clin Psychiatry. 2014.
PMID: 24813414
Search Page
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2008 | 1 |
| 2014 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 0 |
Search Results
5
results
Results by year
Citations
1 article found by citation matchingSearch results
Filters applied: . Clear all
Page 1
Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials.
J Clin Psychiatry. 2014 Apr;75(4):e308-16. doi: 10.4088/JCP.13m08853.
J Clin Psychiatry. 2014.
PMID: 24813414
BACKGROUND: Response to antipsychotics in schizophrenia is highly variable, and determinants are not well understood or used to design clinical trials. OBJECTIVE: We aimed to understand determinants of response to antipsy …
BACKGROUND: Response to antipsychotics in schizophrenia is highly variable, and determinants are not well unders …
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
Health Technol Assess. 2017 Sep;21(49):1-56. doi: 10.3310/hta21490.
Health Technol Assess. 2017.
PMID: 28869006
Free PMC article.
Clinical Trial.
BACKGROUND: When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. ...The size and extent of the side …
BACKGROUND: When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonl …
Evaluation of Prescribing Patterns of Long-Acting Injectable Antipsychotics Within a Community Health System.
J Clin Psychopharmacol. 2019 Sep/Oct;39(5):494-498. doi: 10.1097/JCP.0000000000001095.
J Clin Psychopharmacol. 2019.
PMID: 31425464
IMPLICATIONS/CONCLUSIONS: Inconsistencies were observed between labeling information and clinical practice for LAIAs prescribed within the community health system. ...This analysis may be hypothesis generating for future studies on LAIAs....
IMPLICATIONS/CONCLUSIONS: Inconsistencies were observed between labeling information and clinical practice for LAIAs pr …
How antipsychotics impact the different dimensions of Schizophrenia: a test of competing hypotheses.
Eur Neuropsychopharmacol. 2014 Aug;24(8):1279-88. doi: 10.1016/j.euroneuro.2014.04.001. Epub 2014 Apr 24.
Eur Neuropsychopharmacol. 2014.
PMID: 24862257
Using Structural Equation Modeling in two large [1884 patients] clinical trials in schizophrenia, we compared the model of a common general effect of antipsychotics to models whereby the antipsychotics have multiple and differential effects on t …
Using Structural Equation Modeling in two large [1884 patients] clinical trials in schizophrenia, we compared the model …
Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
J Clin Psychiatry. 2008 Aug;69(8):1281-6. doi: 10.4088/jcp.v69n0811.
J Clin Psychiatry. 2008.
PMID: 18642974
Clinical Trial.
OBJECTIVE: Long-acting risperidone administered intramuscularly biweekly is approved for the management of schizophrenia. However, dosing of long-acting antipsychotics is frequently extended in clinical practice, and a recent clinical trial has …
OBJECTIVE: Long-acting risperidone administered intramuscularly biweekly is approved for the management of schizophrenia. However, do …
Cite